Know yourself, know your enemy, and you will never be defeated

Understanding Cholangiocarcinoma

Overview of Hong Kong

Bile Duct Cancer Incidence and Survival Rate: A Rare but Aggressive Cancer in Hong Kong

Cholangiocarcinoma occurs in the bile ducts between the liver and the duodenum. Although the bile ducts are small, they can still develop cancer, with incidence rates varying by region. According to 2016 statistics from the European Network for the Study of Cholangiocarcinoma, Canada and the U.S. reported 0.35 and 1.6 cases per 100,000 people, respectively, while most European countries, such as the U.K. and France, had rates of 2 to 3 cases per 100,000, making cholangiocarcinoma relatively rare in those regions. In contrast, Asia faces a more severe situation, with Taiwan reporting 4.7 cases per 100,000 people. At the same time, Shanghai and central Thailand recorded rates as high as 7.55 and 14.4 per 100,000, significantly exceeding those in Western countries.

Like other cancers, cholangiocarcinoma can occur at any age, but the risk generally increases with age. Data from the American Cancer Society shows that the average age at diagnosis for intrahepatic and extrahepatic cholangiocarcinoma in the U.S. is 70 and 72, respectively.

Although rare, cholangiocarcinoma poses a serious threat. According to a study by American researcher James E. Everhart, while the 1-year mortality rate has improved, the 5-year survival rate remains persistently below 10%. Advanced-stage cholangiocarcinoma typically has an overall survival period of just 12 to 14 months, making it one of the most lethal forms of cancer.

In simple terms, cholangiocarcinoma develops when DNA mutations in the bile ducts cause uncontrolled cell growth, leading to tumour formation. However, the medical community has yet to reach a consensus on the exact cause of these genetic mutations. Some cases may be triggered by inflammation, while others have no clear origin and may even result from random events without obvious external factors.

That said, cholangiocarcinoma is not entirely unpredictable. Evidence suggests the following factors can trigger or increase the risk of developing the disease:

  • Primary sclerosing cholangitis (PSC): An inflammatory bile duct disease associated with ulcerative colitis, leading to duct hardening, scarring, and eventual tumour formation.
  • Chronic liver disease: Certain liver conditions can cause scarring (cirrhosis), increasing the risk of cholangiocarcinoma.
  • Congenital bile duct abnormalities: Some individuals are born with bile duct cysts, which can lead to abnormal expansion or twisting, raising cancer risk.
  • Liver fluke infection: More common in Southeast Asia, this occurs when undercooked fish parasites infect the liver, potentially leading to cholangiocarcinoma.

In addition to these conditions, age remains a key risk factor, with cholangiocarcinoma predominantly affecting older adults. Long-term smoking habits also increase the likelihood of developing the disease.

Symptoms of Cholangiocarcinoma

Common Bile Duct Cancer Symptoms: Jaundice, Tea-Colored Urine, and Skin Itching

Most cholangiocarcinoma cases are either intrahepatic (within the liver) or hilar (at the junction of the bile ducts). Intrahepatic cholangiocarcinoma develops in the small bile ducts inside the liver. In its early stages, it often lacks distinct symptoms, with patients possibly experiencing only mild discomfort such as flank pain, nausea, loss of appetite, fatigue, and weight loss—symptoms easily overlooked or attributed to other causes. By the time noticeable signs appear, the cancer is often at an advanced, incurable stage.

Hilar cholangiocarcinoma, on the other hand, forms at the junction of the bile ducts outside the liver. Since it frequently causes bile duct obstruction, patients typically exhibit symptoms like itchy skin, jaundice (yellowing of the skin and eyes), dark urine, and pale stools. Some may also develop acute cholangitis, leading to fever, chills, and abdominal pain.

Common Diagnostic Methods

Diagnostic Methods for Cholangiocarcinoma

Due to the bile ducts’ deep location in the body, small tumours are rarely detected during routine check-ups. As mentioned earlier, many patients are diagnosed only after the cancer has spread significantly. Therefore, individuals with conditions strongly linked to cholangiocarcinoma, such as inflammatory bowel disease, primary sclerosing cholangitis, or intrahepatic bile duct stones, should undergo regular screenings to catch potential cancer early.

If the doctor suspects cholangiocarcinoma, initial examinations will assess for abdominal swelling, fluid accumulation, pain, and signs of jaundice (yellowing of the skin or eyes).

Further tests may include:

  • Liver Function Tests: Blood tests to measure bilirubin and alkaline phosphatase levels. Elevated levels may indicate bile duct obstruction but do not confirm cancer, as early-stage intrahepatic cholangiocarcinoma can present with normal liver function.
  • Tumour Markers:
    • CA19-9: A protein often overproduced by cholangiocarcinoma. However, elevated CA19-9 can also result from bile duct inflammation or blockage, and some cancer patients may have normal levels.
    • CEA (Carcinoembryonic Antigen): Less than half of cholangiocarcinoma patients show elevated CEA levels.
  • Imaging Examination:
    • Computed tomography (CT) Scan: Evaluates tumour size and spread to nearby organs, though small bile duct tumours may be missed.
    • MRI Scan: Assesses tumour invasion. Additional specialised imaging may include:
      • ERCP (Endoscopic Retrograde Cholangiopancreatography): A scope is passed through the mouth to inject dye into the bile ducts, highlighting blockages.
      • MRCP (Magnetic Resonance Cholangiopancreatography): A non-invasive alternative to ERCP, using natural tissue contrast to image bile ducts.
      • PTC (Percutaneous Transhepatic Cholangiography): A needle injects dye directly into the liver’s bile ducts for X-ray imaging.
  • PET Scan: Detects distant metastases, commonly to the peritoneum, lymph nodes, lungs, or bones.

After diagnosis, further staging determines the cancer’s progression based on tumour size, lymph node involvement, and distant spread. Staging differs for intrahepatic and hilar cholangiocarcinoma.

Intrahepatic Cholangiocarcinoma
StageDescription
0The tumour is confined to the innermost layer of the bile duct and has not spread.
IAThe tumour is no more than 5 cm in diameter and has not invaded nearby blood vessels or spread to lymph nodes.
IBThe tumour is larger than 5 cm in diameter but has not invaded nearby blood vessels or spread to lymph nodes.
IIThe tumour has extended into nearby blood vessels, or at least two tumours, with or without vascular invasion, but it has not spread to lymph nodes.
IIIAThe tumour has grown and penetrated the peritoneum, the outer lining of the abdomen, but has not spread to lymph nodes.
IIIBThe tumour has directly grown into areas outside the liver but has not invaded lymph nodes or spread to lymph nodes but not to distant tissues.
IVThe tumour can be any size and may or may not involve areas outside the bile duct or lymph nodes, but it has spread to distant tissues, including bones or lungs.
Perihilar Cholangiocarcinoma
StageDescription
0The tumour is confined to the innermost layer of the bile duct and has not spread.
IThe tumour has grown into the muscle or fibrous tissue layer of the bile duct wall but has not invaded lymph nodes.
IIThe tumour has grown through the bile duct wall into nearby fat or liver tissue, but has not spread to lymph nodes.
IIIAThe tumour extends into branches of the main blood vessels on one side of the liver but has not reached lymph nodes or distant tissues.
IIIBThe tumour has invaded the liver’s main blood vessels or branches on both sides, or it has spread to the bile ducts on one side and the main blood vessels on the other, but it has not reached lymph nodes or distant tissues.
IIICThe tumour can be any size and may or may not have grown outside the bile duct or into nearby blood vessels, but it has spread to 1 to 3 nearby lymph nodes without reaching distant tissues.
IVAThe tumour can be any size and may or may not have grown outside the bile duct or into nearby blood vessels, but it has spread to 4 or more nearby lymph nodes without reaching distant tissues.
IVBThe tumour can be any size and may or may not have grown outside the bile duct, into nearby blood vessels, or lymph nodes, but it has spread to distant tissues such as bones, lungs, or liver parts.

Main Treatment Methods

Bile Duct Cancer Treatment Methods: Surgical Resection and Biliary Drainage Options

Upon diagnosis, doctors will determine the most suitable treatment plan for patients with confirmed cholangiocarcinoma. The details are as follows:

  • Surgery:
    This is theoretically the most curative and preferred treatment option. If the patient’s liver function, tumour size, and location are suitable, the surgeon will remove the tumour and surrounding tissue. However, since intrahepatic cholangiocarcinoma symptoms are often subtle, patients are usually diagnosed at a later stage, limiting the effectiveness of tumour removal. For perihilar cholangiocarcinoma, although jaundice symptoms are noticeable, surgery in the hepatic hilum or near the common bile duct is highly challenging due to the dense network of blood vessels and nerves in the area.
  • Chemotherapy:
    This method is commonly used for advanced-stage cholangiocarcinoma when the tumour is unresectable. It aims to alleviate symptoms, shrink the tumour as much as possible, and prolong the patient’s life. While chemotherapy itself causes side effects, newer drugs such as Gemcitabine and Oxaliplatin have significantly reduced side effects compared to traditional chemotherapy.
  • Radiation Therapy:
    Radiation therapy may be used if the tumour is still small but cannot be surgically removed. High-energy beams are directed at the tumour externally, or radioactive material is placed near the tumour internally to destroy cancer cells.
  • Photodynamic Therapy (PDT):
    A light-sensitive chemical is injected into the patient’s vein, triggering a reaction that kills rapidly growing cancer cells. However, this method is typically palliative, and patients require additional treatments.
  • Biliary Drainage:
    This non-surgical approach redirects bile flow around the tumour or places a stent to keep the bile duct open if blocked by the tumour. It is often used to relieve symptoms of cholangiocarcinoma.
  • Liver Transplantation:
    This is an option for perihilar cholangiocarcinoma, where a donor liver is transplanted into the patient. However, this method does not eliminate the risk of cholangiocarcinoma, as the cancer may still recur.

Healthy Living

Post-Bile Duct Cancer Surgery Care: Dietary Adjustments and Complication Prevention

After surgery, doctors may require follow-up monitoring. Patients should attend all scheduled medical appointments to ensure proper recovery and detect any potential complications early. If necessary, doctors may perform X-rays or other tests to assess the likelihood of cancer recurrence.

Prevention Methods

Bile Duct Cancer Prevention: How to Avoid Chronic Biliary Inflammation?

As mentioned earlier, the exact cause of cholangiocarcinoma remains unclear, and no specific prevention method has been established. However, to reduce risk factors, you should avoid or quit smoking, limit alcohol consumption, maintain a healthy weight, and take measures to prevent liver diseases, thereby lowering the chances of developing cholangiocarcinoma.

Frequently Asked Questions

Cholangiocarcinoma FAQs

What is the difference between cholangiocarcinoma and liver cancer?

Cholangiocarcinoma is a type of liver cancer. In terms of location, the liver sits below the diaphragm and to the right of the stomach, while the bile ducts are located beneath the liver. Liver cancer refers to any malignant tumour that develops in the liver, with primary liver cancer being one category. About 10% of primary liver cancer cases are cholangiocarcinoma.

How can cholangiocarcinoma be detected early?

Early-stage cholangiocarcinoma often shows no obvious symptoms, and late-stage cases may not be suitable for surgical removal. Therefore, regular (or doctor-recommended) health check-ups are crucial. If cholangiocarcinoma is detected, it is more likely to be at an earlier stage, making surgical intervention easier.

Some early-stage patients may experience pain in the upper right abdomen, fatigue, or sudden weight loss. If these symptoms occur, medical attention should be sought promptly to determine the cause. However, these signs can also result from minor conditions unrelated to cholangiocarcinoma, so maintaining a healthy lifestyle and regular check-ups remain essential.

Are there any foods or medications that can prevent or treat cholangiocarcinoma?

Currently, aside from chemotherapy drugs that help manage symptoms, no other foods or medications have been conclusively proven to prevent or treat cholangiocarcinoma. According to the Mayo Clinic, a 2016 study involving nearly 4,800 patients suggested that aspirin might reduce the risk of cholangiocarcinoma progression. However, aspirin’s long-term effectiveness and safety in cancer prevention require further research.

What should I do if I notice early signs of cholangiocarcinoma?

Most early symptoms of cholangiocarcinoma are nonspecific, such as side pain, loss of appetite, or fatigue, common complaints among urban populations. Even for perihilar cholangiocarcinoma, which has more noticeable symptoms like itchy skin and yellowing eyes, these signs are not exclusive to the disease.

If you experience these symptoms, there is no need for excessive worry. However, if they persist or worsen, seek medical advice promptly to determine the underlying cause and assess the possibility of cholangiocarcinoma.

What lifestyle adjustments should I make after a cholangiocarcinoma diagnosis?

It is natural to feel concerned after a cancer diagnosis, but excessive anxiety is unnecessary. Please consult your doctor for professional insights, including their prognosis and treatment recommendations, to help you plan accordingly. Additionally, confide in trusted individuals such as family, friends, or social workers to share your feelings and receive appropriate support, helping you navigate this challenging time.




▣ The information on this website has been reviewed by the HEAL Medical Team and is regularly updated according to the most recent clinical evidence. All content is provided for general informational purposes only and should not replace professional medical advice. Please consult your doctor or another qualified healthcare professional for personalized medical guidance.

Contact Us

Our centre operates from Monday to Friday, 09:00 AM to 5:30 PM, and Saturday, 09:00 AM to 1:00 PM. For appointments or to speak with our staff, please call +852 3598 9090.

Should you need to contact us outside business hours, kindly leave a message, and we’ll get back to you as soon as possible.

×